China SXT Pharmaceuticals (SXTC) Equity Ratio (2018 - 2025)

China SXT Pharmaceuticals' Equity Ratio history runs 8 years deep, the most recent figure standing at 0.71 for Q1 2025.

• In Q1 2025, Equity Ratio rose 18.32% year-over-year to 0.71; the TTM figure through Mar 2025 stood at 0.71 (up 18.32% YoY), while the FY2025 annual figure was 0.71, up 18.32% from the prior year.
• Equity Ratio was 0.71 for Q1 2025 at China SXT Pharmaceuticals, up from 0.6 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.71 in Q1 2025 to a low of 0.46 in Q1 2021.
• Historically, Equity Ratio has averaged 0.55 across 5 years, with a median of 0.5 in 2023.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio rose 3.69% in 2023, then climbed 21.17% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.46 in 2021, then grew by 3.77% to 0.48 in 2022, then gained by 3.69% to 0.5 in 2023, then gained by 21.17% to 0.6 in 2024, then rose by 18.32% to 0.71 in 2025.
• The last three Equity Ratio figures came in at 0.71 (Q1 2025), 0.6 (Q1 2024), and 0.5 (Q1 2023), per Business Quant data.